局部枸橼酸抗凝在接受连续性肾脏替代治疗的肝病合并急性肾损伤中的应用效果观察

宁琪琪; 高原; 段美丽; 刘海霞; 孟庆华; 于红卫; 胡中杰; 朱跃科

doi:10.3969/j.issn.1001-5256.2020.05.021

局部枸橼酸抗凝在接受连续性肾脏替代治疗的肝病合并急性肾损伤中的应用效果观察

DOI: 10.3969/j.issn.1001-5256.2020.05.021

1. 首都医科大学附属北京佑安医院肝病重症医学科
2. 首都医科大学附属北京友谊医院重症医学科

基金项目:

国家科技重大专项（2018ZX10302-206-003-007）；北京市丰台区卫生计生系统科学研究项目（2017-60）；

详细信息

中图分类号: R575;R692
计量
- 文章访问数: 1204
- HTML全文浏览量: 83
- PDF下载量: 136
- 被引次数: 0
出版历程
- 出版日期: 2020-05-20

Efficacy and safety of regional citrate anticoagulation in patients with severe liver diseases and acute kidney injury receiving continuals renal replacement therapy

Department of Severe Liver Disease, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

摘要

摘要:
目的探讨在接受连续性肾脏替代治疗（CRRT）的严重肝病合并急性肾损伤（AKI）患者中应用滤器局部枸橼酸抗凝（RCA）的有效性及安全性。方法回顾性收集2016年1月-2019年3月于首都医科大学附属北京佑安医院和首都医科大学附属北京友谊医院行RCA-CRRT的175例肝病合并AKI患者（肝病组）和285例非肝病合并AKI患者（非肝病组）的住院病历资料以及首次CRRT记录资料。观察并比较患者治疗前后肝肾功能生化指标、血气分析、乳酸、钙离子(iCa2+)和总钙(tCa2+)的变化、滤器平均运行寿命、不良反应等。符合正态分布的计量资料组内比较采用配对t检验,两组间比较采用独立样本t检验;不符合正态分布的计量资料两组间比较采用Mann-WhitneyU检验。计数资料两组间比较采用χ2检验。采用Kaplan-Meier生存曲线分析两组间的滤器运行寿命并应用log-rank检验进行比较。结果 CRRT前,肝病组患者ALT、AST、TBil、BUN水平均显著高于非肝病组（P值均<0. 05）。肝病组和非肝病组患者经治疗后,iCa<...
- 肝疾病 /
- 急性肾损伤 /
- 肾替代疗法 /
- 柠檬酸盐类
Abstract:
Objective To investigate the efficacy and safety of regional citrate anticoagulation(RCA) in patients with severe liver diseasesand acute kidney injury(AKI) receiving continuous renal replacement therapy(CRRT).Methods A retrospective analysis was performedfor the medical records and first-time CRRT data of 175 liver disease patients with AKI(liver disease group) and 285 non-liver diseasepatients with AKI(non-liver disease group) who underwent RCA-CRRT in Beijing You' an Hospital and Beijing Friendship Hospital,Capital Medical University, from January 2016 to March 2019. The two groups were compared in terms of the changes in hepatic and renalfunction markers, blood gas parameters, lactic acid, ionized calcium(iCa2+), and total calcium(tCa2+) after treatment, as well as themean operation life of filter and adverse reactions. The pairedt-test or the independent samplest-test was used for comparison of normallydistributed continuous data between two groups, and the Mann-WhitneyUtest was used for comparison of non-normally distributed contin-uous data between two groups; the chi-square test was used for comparison of categorical data between two groups. The Kaplan-Meier sur-vival curve was used to analyze the operation life of filter in the two groups, and the log-rank test was used for comparison.Results BeforeCRRT, the level of ALT、AST、TBil、BUN in liver disease group were significantly higher than those in non-liver disease group(allP<0. 05). After treatment, iCa2+, tCa2+, pH value, and base excess basically returned to normal, and there were significant differences inthe same group before and after treatment(allP< 0. 05). Compared with the non-liver disease group, the liver disease group had a signifi-cantly higher incidence rate of citrate accumulation(tCa2+/iCa2+>2. 5) during treatment(12% vs 2. 2%,χ2 =18.65,P< 0. 001).There was no significant difference in the mean operation life of filter between the liver disease group and the non-liver disease group(32. 20 ± 24. 99 h vs 32. 96 ± 18. 93 h,t =0.346,P> 0. 05) and there was also no significant difference in the 48-hour survival rate withfilter between the two groups(28. 1% vs 26. 9%,χ2 =1.356,P= 0. 381). No adverse reaction associated with citrate accumulation wasobserved.Conclusion In patients with severe liver diseases, although RCA used in CRRT may induce a high incidence rate of citrate accu-mulation, it can achieve a satisfactory anticoagulant effect and is relatively safe.
- liver diseases /
- acute kidney injury /
- renal replacement therapy /
- citrates

HTML全文

参考文献(17)

[1] DAVENPORT A, SHEIKH MF, LAMB E, et al. Acute kidney injury in acute-on-chronic liver failure:Where does hepatorenal syndrome fit?[J]. Kidney Int, 2017, 92(5):1058-1070.

[2] ZHAI XR, XU X, CHEN J, et al. Effect of response at 48 hours of treatment of acute kidney injury on short-term prognosis of hepatitis B virus-associated acute-on-chronic liver failure[J]. J Clin Hepatol, 2019, 35(9):2001-2005.(in Chinese）翟兴冉，许祥，陈婧，等．急性肾损伤治疗48小时应答与否对HBV相关慢加急性肝衰竭短期预后的影响[J]．临床肝胆病杂志，2019, 35(9):2001-2005.

[3] XU MM, CHEN Y. Predictive factors for acute kidney injury in patients with liver cirrhosis[J]. J Clin Hepatol, 2018, 34(10):2124-2129.(in Chinese）徐曼曼，陈煜．肝硬化合并急性肾损伤的尿液相关预测因素分析[J]．临床肝胆病杂志，2018, 34(10):2124-2129.

[4] CHENG XS, TAN JC, KIM WR. Management of renal failure in end-stage liver disease:A critical appraisal[J]. Liver Transpl, 2016, 22(12):1710-1719.

[5] ANGELI P, GINES P, WONG F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J]. Gut, 2015, 64(4):531-537.

[6] WU MY, HSU YH, BAI CH, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy:A meta-analysis of randomized controlled trials[J]. Am J Kidney Dis, 2012, 59(6):810-818.

[7] WEI XH, YE GL, LIU WY, et al. Clinical application of regional citrate anticoagulation in continuous renal replacement therapy after cardiopulmonary bypass[J]. Traum Crit Med, 2018, 6(1):48-50.(in Chinese）魏晓华，叶光磊，刘文悦，等．局部枸橼酸抗凝在体外循环术后患者连续性肾替代治疗中临床应用[J]．创伤与急危重病医学，2018, 6(1):48-50.

[8] SCHULTHEIβC, SAUGEL B, PHILLIP V, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure:A prospective observational study[J]. Crit Care, 2012, 16(4):r162.

[9] COINTAULT O, KAMAR N, BORIES P, et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions[J]. Nephrol Dial Transplant, 2004,19(1):171-178.

[10] LINK A, KLINGELE M, SPEER T, et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients[J].Crit Care, 2012, 16(3):r97.

[11] APSNER R, SCHWARZENHOFER M, DERFLER K, et al. Impairment of citrate metabolism in acute hepatic failure[J].Wien Klin Wochenschr, 1997, 109(4):123-127.

[12] KHADZHYNOV D, SCHELTER C, LIEKER I, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation[J]. J Crit Care, 2014, 29(2):265-271.

[13] MEHTA RL, McDONALD BR, WARD DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months[J]. Contrib Nephrol, 1991, 93:210-214.

[14] SLOWINSKI T, MORGERA S, JOANNIDIS M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure:The Liver Citrate Anticoagulation Threshold(L-CAT)observational study[J]. Crit Care, 2015, 19:349.

[15] KALEMBA KM, WANG Y, XU H, et al. Glycerol induces G6pc in primary mouse hepatocytes and is the preferred substrate for gluconeogenesis both in vitro and in vivo[J]. J Biol Chem,2019, 294(48):18017-18028.

[16] AGARWAL B, SHAW S, SHANKAR HARI M, et al. Continuous renal replacement therapy(CRRT)in patients with liver disease:Is circuit life different?[J]. J Hepatol, 2009, 51(3):504-509.

[17] WANG W, CHANG P, LIU ZG, et al. Regional citrate anticoagulation in critical patients with liver dysfunction[J]. Chin J Crit Care Med, 2016, 36(1):52-55.(in Chinese）王伟，常平，刘占国，等．局部枸橼酸抗凝在重症患者肝功能异常中的应用[J]．中国急救医学，2016, 36(1):52-55.

施引文献

资源附件(0)

访问统计